Emaretamig

艾玛妥米单抗

Report date: 2026/04/16 20:00:17

Base Information

Drug NameEmaretamig
Drug Alias NameASP-2138
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CLDN18Anti-CD3
TargetsClaudin-18 splice variant 2T cell surface glycoprotein CD3
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsPancreatic NeoplasmsStomach Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoItaly +[8] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAstellas Pharma Global Development IncXencor Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstellas (China) Investment Co LtdXencor IncAstellas Pharma Inc +[4] 
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsPancreatic NeoplasmsStomach Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A